Benzinga | Nov 19, 2021 05:29AM EST

BMO Capital Initiates Coverage On Vertex Pharmaceuticals with Market Perform Rating, Announces Price Target of $202

BMO Capital analyst Evan Seigerman initiates coverage on Vertex Pharmaceuticals (NASDAQ:VRTX) with a Market Perform rating and announces Price Target of $202.